“…In cancer transcriptomics, ML and DL models have been applied to classify different cancer subtypes and cell populations [ 17 , 18 , 19 , 20 ], characterize tumor immune microenvironment [ 21 , 22 , 23 , 24 , 25 ], discover new prognostic biomarkers [ 26 , 27 , 28 ], assess and predict disease recurrence and patient survival [ 29 , 30 , 31 , 32 ], identify new putative actionable vulnerabilities [ 33 , 34 ], and predict tumor antigen immunogenicity [ 35 ] ( Figure 2 ).…”